Xenon Pharmaceuticals Inc. (XENE) Fundamental Analysis: Bull vs. Bear Case

XENE

Xenon Pharmaceuticals Inc.

Fundamental data last updated:September 6, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

CA

Next Earnings Date

Pending Announcement

Business Summary

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

VALUATION

P/E

-12.49

Market Cap ($M USD)

$4.33B

Forward P/E

11.77 PEG

0.06 PRICE TO SALES

0.00 PRICE TO BOOK

3.58 EV / EBITDA

-9.49

5-Year Average P/E

Free Cash Flow Yield

-7.10%

DCF Value

$2.44

Graham Number

N/A

Price to FCF

-14.08

EV to FCF

-12.33

Earnings Yield

-8.01%

FCF Yield

-7.10%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$4.39

Next Year EPS Growth Estimate

$4.65

Next Year Revenue Growth Estimate

$1.21B

Return on Equity (ROE)

-49.23%

FREE CASH FLOW

Operating Margin

0.00%

Debt-to-Equity

0.01 Piotroski F-Score

2 Altman Z-Score

50.98 Return on Invested Capital (ROIC)

-30.64%

Current Ratio

27.79 Quick Ratio

27.79 Net Debt to EBITDA

1.35 Interest Coverage

0.00 Gross Profit margin

0.00%

FCF PER SHARE

$-3.52

REVENUE PER SHARE

$0.00

Gainseekers Quantitative Analysis

Summary

Xenon Pharmaceuticals Inc. presents a perplexing valuation scenario. Despite a forward P/E of 12.04 suggesting future profitability, the current negative earnings yield and a DCF value far below recent pricing indicate potential overvaluation. The Altman Z-score of 53.18, however, signals robust financial health, suggesting the company is far from distress. The market may be mispricing the stock relative to its intrinsic value, as indicated by the stark contrast between its snapshot price and the DCF value. Investors should weigh the high growth expectations against the current financial metrics.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Xenon Pharmaceuticals is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent reliance on cutting-edge technology aligns with potential AI-driven efficiencies. This positioning could enhance their competitive edge in developing innovative therapies.

The Bull Case

For the value or GARP investor, Xenon Pharmaceuticals offers intriguing potential. Despite a negative ROIC and FCF yield, the forward PEG ratio of 0.058 suggests significant growth at a reasonable price. The company's low debt-to-equity ratio and high current ratio reflect a strong balance sheet, providing a cushion for future investments. These factors, combined with a consensus buy rating, indicate institutional confidence in its growth trajectory.

The Bear Case

However, the bear case is equally compelling. The negative price-to-FCF and earnings yield highlight severe cash flow issues, raising concerns about operational efficiency. The stock's proximity to its 52-week high suggests technical overextension, potentially limiting upside. Additionally, a Piotroski F-Score of 2 indicates weak financial health, challenging the narrative of sustainable growth.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$85.00

Institutional Ownership %

1-Year Beta

0.65 Insider Buying % (6 Mo)

Distance to 52-Week High

16.72%

Distance to 52-Week Low

48.55%

EARNINGS SURPRISE %

0.00%

50-DAY SMA

$56.08

200-DAY SMA

$45.37

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.